Table 3.

Safety assessment after COVID-19 vaccination was scarcely implemented as well as preemptive immunosuppression modification, where mycophenolate adjustment was the most common approach.

		Proportion	[95%_Conf. interval]
Liver function test (LFT) monitoring		0.296	0.221	0.384
Time of LFT monitoring	2 weeks	0.376	0.155	0.665
	1 month	0.382	0.109	0.758
	3 months	0.145	0.022	0.559
	Other	0.097	0.010	0.545
Via report of vaccine monitorization	Telemedicine	0.267	0.087	0.583
	Outpatient clinic	0.627	0.306	0.865
	Patient self-report	0.070	0.015	0.264
	Other	0.036	0.004	0.266
Type or dose of immunosuppression modification pre-vaccine		0.161	0.059	0.373
	CNI reduction	0.093	0.014	0.420
	MF reduction	0.378	0.076	0.819
	MF interruption	0.414	0.104	0.811
	Steroids reduction	0.294	0.036	0.821
	Steroids interruption	0.166	0.016	0.715
	Others	0.073	0.008	0.444

LFT, liver function test; CNI, calcineurin inhibitor; MF, mycophenolate.